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ABSTRACT 
 
SWETA ADHIKARI: Modification of Panobinostat to increase its therapeutic potential to cure 
Multiple Myeloma (Under the direction of Dr. Davita Watkins) 
 
              Panobinostat is a potent histone deacetylase inhibitor that can impede function of a wide 
range of zinc-dependent histone deacetylases. Panobinostat is the first approved histone deacetylase 
inhibitor for the treatment of multiple myeloma, along with other drugs such as Velcade and 
Dexamethasone. Simplistically, it helps to shrink or eradicate tumor growth in multiple myeloma 
patients. However, the treatment has severe adverse effects due to its lack of selectivity. In 
collaboration with Dr. Shana Stoddard (Rhodes College, Memphis TN) and Fatima Rivas (St. 
Jude’s Research Hospital, Memphis TN), our research aims to design a more selective model of 
panobinostat that binds with the human histone deacetylase 8. Model compounds were examined 
and docking scores were computed based on protein X-ray crystal data. Herein, panobinostat 
derivatives having the highest docking score are presented with a synthetic scheme for the first 
target derivative.  The synthesis and characterization by nuclear magnetic resonance (NMR) are 
described. 
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INTRODUCTION 
 
Cancer is a collection of illnesses that involves the uncontrollable growth of abnormal cells 
that have the ability to spread to surrounding tissues within the body. When abnormal cells divide, 
they form tumors that can either be benign (non-cancerous) or malignant (cancerous). In this 
discussion, we will primarily focus on malignant plasma cells that causes multiple myeloma (MM). 
In our immune system, lymphocytes are the most important cells that fight infections and 
other diseases1. T cells and B cells are two major types of lymphocytes. B cells bind to the antigen 
and receives a signal from T cells to divide. The B cells continuously divide and eventually 
transform into plasma cells. Plasma cells, located in bone marrow, produce antibodies that kill 
germs and other infections within the body. When the plasma cells become cancerous, they divide 
rapidly and form a tumor or plasmacytoma in the bone. The cancer associated with the formation 
of more than one tumor in the bone is known as MM. It can lead to fewer white blood cells, 
infections, weaker bones, and kidney problems among other complications. 
MM is found to be an outstanding example of epigenomics dysregulation in human body 
because epigenetic aberrations play an important role in the development of MM2.  Epigenetics 
refers to the complex interactions between the genome and the environment that leads to growth 
and regulation in the body3.
 For the regulatory patterns of gene expression, epigenetic modification 
occurs such as DNA methylation and posttranslational histone modification2. There are high levels 
of epigenetic modifications in the cancer cells that transform the chromatin structure and DNA 
accessibility3. 
One of the most highly studied epigenetic modifications in MM is the histone modification2. 
The overexpression of histone deacetylase (HDAC) leads to hypoacetylation of histones in cancer 
9 
 
cells, resulting in cell survival and multiplication. Aforementioned reasons have led to synthetic 
study of HDAC inhibitors (HDACi) to examine if they help reduce the size of MM tumors. 
Panobinostat is a pan-HDACi that shows a great potential to cure MM, but due to its lack of 
selectivity causes various adverse effects in majority of patients. 
With the hope of developing a better therapeutic treatment, researchers are seeking the 
development of HDACis with high potencies and efficiencies. With the help of our colleagues at 
Rhodes College and St. Jude’s Research Hospital, we were able identify several target molecules 
that show properties that are comparable to those of a leading HDACi known as panobinostat.  
Specifically, our lab contributes to the study by offering synthetic strategies towards these 
molecules.  Herein, a brief background pertaining to the role of HDAC and HDACis is discussed.  
In addition, the synthesis of a panobinostat derivative (TOI) is described in an effort to further study 
its therapeutic applications.  
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BACKGROUND 
1. HDAC 
 
Figure 1: Equilibrium of acetylation and deacetylation during transcription in a normal cell.14 
 
 Typically, during the activation of transcription, acetyl groups are added to an amino acids 
on histones in the DNA by the enzyme histone acetyltransferases (HATs) to form active chromatin7. 
However, HDACs removes acetyl groups from an amino acid on the histone, to control the turning 
on and off of genes during transcription as shown in Figure 1. 
There are four classes of histone deacetylase; class I (HDAC1, HDAC2, HDAC3, HDAC8), 
class II (HDAC 4, HDAC 5, HDAC 6, HDAC 7, HDAC 9, HDAC 10), class III (Sirtuin proteins), 
and class IV (HDAC 11)17. Except for class III, all the HDAC require zinc as a cofactor, therefore 
they are known as zinc dependent HDACs. Class III enzymes are considered a separate type of 
NAD+ dependent enzymes and have a different mechanism of action16. 
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2. Role of HDAC in cancer 
 
Figure 2:  Overexpression of HDAC leads to hypoacetylation in cancer cells.14 
 
A typical characteristic of human cancer is the dysregulation of posttranslational histone 
modification, specifically histone acetylation7. Due to epigenetic modifications, there is a decrease 
in HAT activity and increase in HDAC activity. When HDACs are overexpressed, the tumor 
suppressor genes are repressed during the onset and progression of tumor. It causes unregulated cell 
growth and survival as shown in Figure 2. 
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Figure 3: Hypoacetylation alters the expression of genes causing cancer initiation and progression.15 
 
HDAC alters the expression of tumor suppressing genes and favors the development of 
cancer15. HDAC represses genes resulting in the uncontrolled cell proliferation, loss of 
differentiation, and inhibition of apoptosis. Similarly, during cancer progression, HDAC represses 
genes, resulting in a loss of adhesion, migration, invasion, and angiogenesis. Loss of intercellular 
adhesion allows malignant cells to escape from their site of origin and metastasize. Also, there is 
new growth in the vascular network for adequate supply of oxygen and nutrients and removal of 
waster products for cancer cells through a process called angiogenesis.  
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3. HDACi 
 
Figure 4: HDACi retains the balance between acetylation and deacetylation.14 
 
HDACi induces acetylation of histones in the cancer cells and increases tumor suppressor 
gene activity. This phenomenon results in cell cycle arrest, differentiation, or apoptosis to inhibit 
the proliferation of cancer cells4. 
HDACi have been extracted from natural products or synthesized in the laboratory. Pan-
HDACi is an HDAC inhibitor that has been approved as a drug which acts broadly on all forms of 
zinc- dependent HDACs16. A few examples of pan-HDACi are trichostatin A, vorinostat, and 
panobinostat. However, with the treatment of HDACi, normal cells were found to be quite 
resistant. In our research, we are concentrating on panobinostat, which induces wide range of 
HDACs. 
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4. Panobinostat 
Panobinostat is a potent oral pan-HDACi that has shown high therapeutic potential in its 
ability to inhibit a wide range of HDACs including classes I, II, and IV at nanomolar 
concentrations5. It uses metal-ion coordination to bind with the zinc ion in histone. Thus, it can 
inhibit the zinc-dependent HDACs because of its binding capabilities and selectivity. It is the first 
HDACi approved for the treatment of MM with the combination of other drugs such as velcade and 
dexamethasone in 20158, 9. Velcade is a brand name of the drug bortezomib that interferes with the 
growth of some cancer cells and keeps them from spreading in your body. Similarly, 
dexamethasone is a drug that reduces swelling and inflammation.  
In a clinical trial referred to as PANORAMA1, 193 patients were randomly appointed to 
receive either combination of three drugs: panobinostat, borezomib, and dexamethasone, or 
combination of two drugs (placebo): bortezomib and dexamethasone 8. These patients had already 
received previous treatments, or did not respond to the treatments. During the treatment, the cancer 
had reduced or disappeared in 59% of the patients with the combination of panobinostat in 
comparison to the other 41% without panobinostat. However, 96% of the patients treated with 
panobinostat experienced side effect such as nausea, vomiting, diarrhea, fatigue, and 
thrombocytopenia (deficiency of platelets in the blood) among which 60% experienced far more 
serious side effects6. The median of progression free survival was 10.6 months with panobinostat 
and 5.8 months without it. With the hope of developing a better therapeutic treatment, researchers 
are seeking the development of HDACis with potencies and efficiencies that are similar to that of 
panobinostat.  
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RESULTS AND DISCUSSION 
 
5. Modification of Panobinostat 
In collaboration with colleagues at Rhodes College and St. Jude’s Research Hospital, we 
were able to identify several target molecules that show properties that are comparable to that of 
panobinostat.  
 
Figure 5: Molecular structure of panobinostat 
 
In order to study and model several target molecules, the molecular structure of panobinostat 
was divided into four regions. The blue region is an indole, which cannot be changed in the target 
molecules because it is necessary for protein binding and recognition. N-hydroxyl amine is 
necessary for binding with zinc in histones. In turn, the two regions for interest towards alteration 
and study are the green alkyl group (R1 = methyl) and the purple amino methyl phenyl prop-2-
enamide region. 
The focus of our studies was based on the identification of molecular interactions between 
panobinostat and the protein present in histone human HDAC8. In this case, the noncovalent 
interactions between the protein and panobinostat derivative are pi-pi stacking and hydrogen 
bonding. Computational studies based on protein X-ray crystal data were used to find the docking 
scores of the model compounds. Docking scores are mathematical methods used to predict the 
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strength of non-covalent interaction between two molecules after they have been docked. Docking 
of protein is done to predict the position and orientation of a ligand when it is bound to a protein 
receptor. It can be done by X-ray crystallography to visualize protein structures at the atomic level 
and understand the how proteins interact with other molecules.  
 
Docking Scores of Targets of Interests 
Compound Best Docking 
Score 
Structure 
PANO 9.3381 
 
TOI1 10.2300 
 
TOI2 9.5874 
 
TOI3 8.8060 
  
TOI4 
 
 
 
9.4581 
 
                      ETS1 9.4565 
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ETS2 8.9591 
 
ETS3 8.8402 
 
ETS4 8.7114 
 
ETS5 8.6623 
 
 
Table 1: The docking scores of various molecular structures having organic frameworks similar to 
panobinostat were calculated based on protein X-ray crystal data using SYBYL-x Surflex DOCK program. 
 
 
From the results from Table 1, we can see the rank of docking score  of compounds in 
increasing order is TOI1 (10.2300) > TOI2 (9.5874) > TOI4 (9.4581) > ETS1 (9.4565) > PANO 
(9.3381) > ETS2 (8.9591) > ETS3 (8.8402) > TOI3 (8.8060) > ETS4 (8.7114) > ETS5 (8.6623). 
 
Based on the data, we began to synthesize (E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-
yl)ethylamino]methyl]pyrazine]prop-2-enamide-referred to as  TOI, which outcompeted PANO 
suggesting a strong potential to be an HDACi. 
 
Figure 6: Target of interest 1 (TOI1) having the highest docking score, one which is greater than that of 
panobinostat. 
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The alteration in the structure of TOI is a replacement of a pyrazine instead of a benzene 
ring. Pyrazine contributes to increased selectivity in binding with human histone HDAC, avoiding 
unintended consequences. Our lab contributes to the study by offering synthetic strategies towards 
these molecules. Herein, the synthesis of a panobinostat derivative (TOI) is described in an effort 
to further study its applications. 
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6. Synthesis Scheme 
 
 
Figure 7: The synthesis scheme to achieve TOI1.  
 
 
In the synthesis scheme, the first step is Fischer esterification of carboxylic acid. Then, the 
ester is reduced to aldehyde in the second step. The third step is the Wittig reaction to synthesize 
acrylate. The formyl group is added to the acrylate in the fourth step. Then, the Borch reductive 
amination is done in the sixth step to add the indole amine to the acrylate. Finally, the ester in the 
acrylate is converted to N-hydroxyl amine to achieve TOI1. 
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7a. Fischer Esterification of 5-methyl pyrazine carboxylic acid 
 
 
 
 
 
 
Mechanism: 
 
Fischer esterification is the esterification done by refluxing a carboxylic acid and an alcohol 
in the presence of an acid catalyst. The electrophilic nature of the carbonyl carbon and the 
nucleophilic nature of the alcohol results in the nucleophilic acyl substitution. The water formed in 
the reaction is very likely to hydrolyze the ester, therefore the addition of a molecular sieve to the 
reaction mixture was very important to absorb water.  
As shown in Figure 8, during the esterification, the proton transfer from the sulfuric acid to 
the carbonyl oxygen increases electrophilicity of the carbonyl carbon. Then, the nucleophilic 
oxygen atom of the methanol attacks the carbonyl carbon. The proton from the oxonium ion 
attached to the methyl group is transferred and creates water, which leaves the complex creating a 
new oxonium ion. Finally, deprotonation of the oxonium ion gives the final ester.  
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Figure 8: The mechanism of Fischer esterification of 5-methyl pyrazine carboxylic acid to produce methyl 
5-methyl pyrazine carboxylate. 
 
Procedure: 
To a three neck 500 mL round bottom flask (RBF), 2.75 g of molecular sieve was measured 
and added along with a stir bar. The RBF was flamed dried to create an inert environment. Then, 5 
g of 5-methyl pyrazine carboxylic acid was added in the RBF. The RBF was degassed and gassed 
several times to rid the reaction vessel of air. A volume of 125 mL of anhydrous methanol was 
added to the flask and stirred for few minutes. Slowly, 91 drops of glacial sulfuric acid was added 
of the mixture. The reaction was allowed to stir and reflux overnight11.  
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Extraction: 
        Molecular sieve was filtered off via vacuum filtration through celite. The filtrate was 
evaporated to remove methanol from the product. The product was dissolved in DCM, and washed 
with brine and sodium bicarbonate in a separatory funnel. The organic layered was collected and 
dried over sodium sulfate. The solvent was then evaporated to obtain the product. 
 
NMR: 
 
 
 
Figure 9: 1H NMR of methyl 5-methyl pyrazine carboxylates - (300 MHz, CDCl3) δ 9.29 (1H, s), 8.58 (1H, 
s), 4.03 (3H, s), 2.67 (3H, s) 
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Result: 
The weight of the solid yellow colored sample was 3.08 g. The yield was calculated to be 
56.7%.  
 
Discussion:  
The 1H NMR spectra was recorded on a 300 MHz instrument using CDCl3 solvent. In the 
spectrum, there are two singlets at 9.29 ppm and 8.58 ppm which belong to the two proton signals 
in the aromatic pyrazine ring. The peak at 9.29 ppm belongs to the proton signal (Ha) near the 
carbonyl, whereas the peak at 8.58 ppm belongs to the proton signal (Hb) near methyl group. The 
singlet at 4.03 ppm belongs to the proton signal (Hc) in the methoxy group of the ester. The singlet 
at 2.67 ppm belongs to the proton signal (Hd) for the in methyl group on the pyrazine ring.  Thus, 
we concluded that we produced the desired ester. 
 
7b. Reduction of methyl 5-methyl pyrazine carboxylates 
N
N
O
O
N
N
H
O
methyl 5-methylpyrazine-2-carboxylate 5-methylpyrazine-2-carbaldehyde
DIBAL-H
 
 
 
Mechanism: 
 
In the mechanism of the reaction, DIBAL-H acts as an electrophilic reductant. In the first 
step, the nucleophilic lone pair of carbonyl oxygen attacks the electrophilic aluminum in DIBAL-
H and the DIBAL-H then provides the hydride to the carbonyl oxygen forming the tetrahedral 
intermediate. Then, the methoxy group leaves the intermediate to generate negative charge on O in 
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the leaving group and positive charge on O bonded to Al. Then, the methoxy group attacks  Al 
forming the aldehyde. 
 
N
N
O
O
Al
H
N
N
O
O
Al
N
N
O
AlN
N
H
O
O
 
 
Figure 10: The mechanism of Reduction Reaction of methyl 5-methyl pyrazine carboxylate to produce 5-
methyl pyrazine-2-carbaldehyde. 
 
Procedure: 
 Under dry and inert conditions, 1.06 g of methyl 5-methyl pyrazine carboxylate was added 
to the round bottom flask. Then, 10 mL of dry DCM was added to the RBF. The reaction was placed 
in ice bath to reduce the temperature to - 78˚C. After the reaction reached -78˚C, 10 mL of DIBAL-
H was added12. The reaction was allowed to stir for three hours.  
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NMR: 
 
Figure 11: 1H NMR of 5-methyl pyrazine-2-carbaldehyde (300 MHz, CDCl3) δ 10.13 (1H, s), 9.06 (1H, s), 
8.62 (1H, s), 2.72 (3H, s) 
 
Result: 
The oily brown crude weighed 4.4133g. The yield was considered 100%, solvent was removed and 
crude was used as obtained. 
 
Discussion: 
 In the reduction reaction, DIBAL-H is used to reduce ester to aldehyde. In the reaction, the 
temperature was maintained around -78°C to prevent the further reduction to alcohol. To monitor 
the course of the reaction and the formation of aldehyde, DIBAL-H was added in small aliquots. 
After the reaction reached -78˚C, 5 mL of DIBAL-H was added. The reaction was allowed to stir 
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for an hour. A 2.5 mL solution of DIBAL-H was added to the mixture and stirred for another hour. 
Finally, 2.5 mL of DIBAL-H was added and the reaction was let stir for 1 hour.  
 Also, the aqueous workup of the crude was avoided in this experiment since the workup 
always favored the hydrate formation and produced very low yield of the aldehyde. In presence of 
acid media (work-up), an aldehyde can form an aldehyde hydrate. Although, the aldehyde hydrate 
may be present in low equilibrium concentration, those molecules bearing an electron withdrawing 
group (e.g. pyrazine) can yield stabilized hydrates (not shown, 1H NMR signals at 5.49 and 4.72 
ppm). Therefore, the aqueous work up was avoided and the crude was evaporated and used in the 
next step. 
The 1H NMR spectrum was recorded on a 300 MHz instrument using CDCl3 solvent. The 
singlet peak at 10.13 ppm belongs to the proton signal (Hc) in the aldehyde. This peak confirms the 
presence of aldehyde in the product. The singlet peak at 9.06 ppm belongs to the proton (Ha) in the 
aromatic ring near carbonyl compound. The singlet at 8.62 ppm belongs to the proton (Hb) in the 
aromatic region near the methyl group. The singlet at 2.72 ppm belongs to the proton (Hd) in methyl 
group.  
Although we had complication regarding the aqueous workup, we were successful at 
obtaining the aldehyde. 
 
7c. Wittig Reaction 
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Mechanism: 
    Wittig reaction is a reaction of an aldehyde and ylide to form an alkene product and triphenyl 
phosphine oxide byproduct. The mechanism includes the nucleophilic addition of the ylide to the 
electrophilic carbonyl group forming the four membered ring. Then, the ring collapses to form a 
strong O=P bond and an alkene bond due to ring strain and stable O=P bond.  
 
 
   
 Figure 12: The mechanism of Wittig reaction of 5-methyl pyrazine-2-carbaldehyde to synthesize ethyl   (E)-
3-(5-methyl pyrazine-2-yl) acrylate. 
 
Procedure: 
In a dry and inert atmosphere, 1.39 g of ethoxy carbonyl methylane triphenyl phosphorene (ylide) 
and 20 mL of DCM was added to the round bottom flask. The remaining 20 mL of DCM was used 
to dissolve 0.5 g of carbaldehyde in a separate RBF. The RBF was then put in the dry ice bath to 
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decrease the temperature to -78˚C. After the RBF was at -78˚C, the carbaldehyde solution was 
transferred to the RBF through a cannula. Then the reaction ran at -78˚C for 10 minutes. After that, 
the reaction ran for 1 hour at RT13. 
 
 Extraction: 
After the reaction was done, the crude was quenched in aq. ammonium chloride and washed with 
brine in a separatory funnel. The organic layer was extracted and dried in anhydrous magnesium 
sulfate. The acrylate was obtained after the solvent was evaporated. The NMR revealed a lot of 
impurities in the product. Thus, the product was purified via column chromatography. 
 
Purification: 
The column was done using a 50:50 hexane and ethyl acetate solution. Acrylate eluted in the first 
few test tubes. The bright yellow acrylate solution was evaporated. 
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NMR: 
 
 
Figure 13: 1H NMR of Ethyl (E)-3-(5-methyl pyrazine-2-yl) acrylate (300 MHz, CDCl3) δ 8.54 (1H, s), 
8.49(1H, s), 7.64-7.69 (1H, d), 6.93-6.98 (1H, d), 4.24-4.31 (2H, q), 2.59 (1H. s), 1.31-1.33 (3H, t); *solvent 
impurity: ethyl acetate 
 
 
Result: 
   The final weight of yellow solid crystals was 0.44 g. The percent yield was 57.9%. The 
stereochemistry of the alkene product was trans (E) based on the coupling constant for the alkene 
proton signal. 
 
Discussion: 
     The 1H NMR spectra was recorded on a 300 MHz instrument using CDCl3 solvent. The singlet 
peak at 8.54 ppm belongs to the proton signal (Ha) in the pyrazine ring near the alkene group. The 
singlet peak at 8.49 ppm belongs to the proton signal (Hb) in the pyrazine ring near methyl group. 
The doublet at 7.64-7.69 ppm belongs to the proton signal (Hf) in in the alkene group next to the 
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pyrazine ring. The doublet at 6.93-6.98 ppm belongs to the proton signal (He) in the alkene group 
next to the carbonyl group. The ylide used in the reaction is very stable, thus it favors a particular 
stereochemistry of the product. The j-j coupling constant for the alkene proton signal was calculated 
to be 16, which confirms that the stereochemistry of the product is trans. The quartet at 4.24-4.31 
ppm belongs to the proton (Hg) in methyl group of the ester. The singlet (Hd) at 2.59 ppm belongs 
to methyl group on the pyrazine ring. Also, the triplet at 1.31-1.33 ppm belongs to the methylene 
group (Hc) of the ester. In conclusion, we successfully obtained acrylate from the aldehyde by the 
Wittig reaction. 
 
7 d.  Synthesis of  ethyl (E)-3-(5- ((E)-2-(dimethyl amino) vinyl) pyrazine-2-yl) acrylate 
 
 
N
N
O-Et
O
N
N
O-Et
O
N,N DMF dimethyl acetal
ethyl (E)-3-(5-methylpyrazin-2-yl)acrylate
ethyl (E)-3-(5-((E)-2-
(dimethylamino)vinyl)pyrazin-2-yl)acrylate
N
 
 
Mechanism: 
The nucleophilic methoxy ion is formed during the equilibrium of N,N-dimethyl formamide 
dimethyl acetal. It attacks the proton in the methyl group on the pyrazine, making the methyl anion 
nucleophilic. The methyl anion then attacks the imine derivative. Finally, the double bond forms 
due to the loss of methoxy group to form ethyl (E)-3-(5- ((E)-2-(dimethyl amino) vinyl) pyrazine-
2-yl) acrylate. 
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Figure 14: The mechanism to synthesize ethyl (E)-3-(5- ((E)-2-(dimethyl amino) vinyl) pyrazine-2-yl) 
acrylate (enamine). 
 
Procedure: 
Under dry and inert atmosphere, 0.64g of acrylate, 1.75 mL N, N dimethyl formamide dimethyl 
acetal, and 2 mL anhydrous N,N-dimethyl formamide was added to 50 mL RBF. The reaction 
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mixture was heated to 90 ˚C for an hour. Then, the reaction mixture was heated at 125 ˚C for two 
hours. The reaction mixture was cooled to 25 ˚C. 
 
NMR: 
 
Figure 15: 1H NMR of ethyl (E)-3-(5- ((E)-2-(dimethyl amino) vinyl) pyrazine-2-yl) acrylate * (300 MHz, 
CDCl3). Solvent impurities- DMF and starting material 
 
Result: 
The reaction was only 35% complete according to 1H NMR data. 
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Discussion: 
In the NMR, we can see the presence of the product shown by the asterisks as well as starting 
material and the solvent, DMF.  The peak assignments are not conclusive however, the product was 
appears to be 35% of the reaction mixture monitored over several days. In the future, we plan to 
run the reaction at a higher temperature and for longer period of time. If the reaction does not go 
forward, we will seek an alternative reaction. 
 
 
CONCLUSION 
 
Panobinostat shows high therapeutic potential to cure multiple myeloma. However, due to 
the lack of selectivity, it often produces unwanted consequences. Since it is a potential drug, our 
colleagues at Rhodes College studied and designed a derivative of panobinostat, which has better 
docking score than panobinostat itself. We then designed a multi-step synthetic route to synthesize 
the target. Among the seven steps, we were able to complete three to four steps. Currently, we have 
methyl (E)-3-(5-methyl pyrazine-2-yl) acrylate which can be produced in up to a 5 g scale. 
We plan to continue the research until early May, and then offer our knowledge to another 
interested student who will continue to work to synthesize the target of interest. In the future, we 
plan to optimize our condition and synthesis route to obtain TOI1. Also, a graduate student will 
take over the project upon completion of the synthesis of TOI1 to work towards the other derivatives 
such as TOI4 and ETS1. 
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